<DOC>
	<DOCNO>NCT00511511</DOCNO>
	<brief_summary>The aim study find simple clinical laboratory parameter predict development hypertension elucidate mechanism hypertension treatment tyrosine kinase inhibitor Sunitinib .</brief_summary>
	<brief_title>Angiogenesis Inhibitors Hypertension : Clinical Aspects</brief_title>
	<detailed_description>Inhibition angiogenesis antibody vascular endothelial growth factor ( VEGF ) VEGF receptor antagonists become establish treatment cancer . An unanticipated side effect angiogenesis inhibitor development hypertension . The pathogenesis hypertension unknown . Not patient develop hypertension . However , know patient patient develop hypertension .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Angiogenesis Inhibitors</mesh_term>
	<criteria>Men woman , either renal cell carcinoma gastro intestinal stromal tumor ( GIST ) intend treat solely Sunitinib ( singleagent treatment ) consider fit enough treat physician receive Sunitinib .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>hypertension</keyword>
	<keyword>angiogenesis inhibitor</keyword>
	<keyword>tyrosine kinase inhibitor</keyword>
	<keyword>Sunitinib</keyword>
</DOC>